A user's 2.5 months of finasteride, oral minoxidil, and dermarolling treatments for hair loss, with various users giving their opinion on the progress made.
The user shared their hair transplant progress, using saw palmetto, vitamins, biotin, zinc, ginseng, ozonized olive oil, and a dermaroller with serum. They avoid finasteride due to trying for a second child.
The user has been using finasteride every other day and oral minoxidil for hair regrowth, noticing new baby hairs. They are hopeful about regaining hair on their temples.
The user is considering switching from Minoxidil to dutasteride for hair loss treatment but is concerned about the potential for increased shedding. They are seeking advice on whether to wait for the current shedding phase to subside before starting dutasteride.
A user is considering switching from oral to topical treatments for hair loss due to side effects like watery semen and erectile dysfunction. They are currently using oral finasteride and minoxidil and are concerned about potential sexual side effects with topical use.
The user discusses experiencing side effects from topical finasteride but not from oral finasteride, seeking advice on this issue. They mention a gradual increase in oral finasteride dosage with no side effects.
PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.
Stacking 5% minoxidil twice daily, 1.25mg finasteride daily, 6 drops of the Ordinary hair serum with Redensyl each night, 1.5mm dermarolling once a week, Nizoral shampoo twice a week and caffeine shampoo once a week for hair loss treatment.
Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.
OP experienced significant hair shedding after 8 months of using topical minoxidil and plans to start finasteride. They are concerned about hair loss and have scheduled a dermatologist appointment.
The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.
A user shared their progress using liquid minoxidil for hair regrowth and plans to switch to foam minoxidil due to flaking. They asked if the foam version would maintain their results and mentioned considering adding finasteride and a derma pen soon.
The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.
The user is inquiring about alternating daily doses of Minoxidil, taking 5mg one day and 2.5mg the next. They are seeking advice on whether this dosing schedule is acceptable.
User got a hair system after hair transplant and finasteride didn't meet their needs. Hair system cost $200, initial install $150, and user is satisfied with the results.
17M approaching Norwood 2, using topical minoxidil and considering finasteride, oral minoxidil, and pyrilutamide. Plans to study dermatology and possibly get a hair transplant at 25 if treatments don't work.
The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
A user is experiencing hair loss despite using topical minoxidil for 6 months and recently switching to foam, and is considering finasteride but is wary of side effects. Another user suggests continuing treatment and considering finasteride.
The user is considering using 2 vials of Fluridil every other day instead of 1 vial daily for better scalp coverage. They are questioning if this method would be as effective.
A 23-year-old shares their 5-month progress using oral finasteride and minoxidil for hair loss, noting initial reduced shedding and later thicker hair shedding. Users reassure that multiple sheds are normal and indicate progress.
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.
Switching from topical to oral minoxidil caused prolonged hair shedding without regrowth, leading to the use of both topical and oral minoxidil with oral finasteride. Responses to these treatments vary, emphasizing the need for personalized approaches.
Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.
A user is using topical finasteride, minoxidil, and oral finasteride for hair loss but hasn't seen progress yet. They are considering switching to oral finasteride only due to scalp issues from the topical solution, but are advised to continue the current regimen for at least six months to a year.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.
The user is experiencing a second hair shedding phase after 7 months on finasteride, oral minoxidil, and ketoconazole, and is concerned about the sustainability of the treatment. Others encourage continuing the treatment, explaining that shedding is normal and should stabilize over time.
OP shared progress pictures after 7 months of using a topical solution with 0.25% finasteride and 5% minoxidil, prescribed by a dermatologist. OP experienced mild shedding initially and noticed significant growth by the third month.